Mediterranean journal of rheumatology · 2025
The Effectiveness of Infliximab in Treating Vascular Manifestations of Behçet's Disease: A Systematic Review and Meta-Analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bennani Aymane, Benmansour El Khalil, Serraj Khalid
Аннотация
OBJECTIVE: Our study aims to evaluate the effectiveness of anti-tumour-necrosis-factor Infliximab (IFX) in treating patients with severe and/or refractory vascular manifestations of Behçet's disease (BD) through a systematic review and meta-analysis.
METHODS: We searched PubMed, Scopus, Web of Science, and Cochrane Library databases for eligible studies. Meta-analysis of proportions was performed. Heterogeneity was assessed with Cochrane's Q test and I2 statistics. Random effects models were used for all statistical analyses which were conducted on R software (version 4.4.2), PROSPERO registry number CRD42025640970.
RESULTS: Of the 2127 results initially identified, 11 studies with a total of 284 patients were included in the final analysis. Infliximab induced complete vascular response in 78.17% of patients (95% CI 63.11-90.61). The remission rates in the subgroups of patients with pulmonary artery aneurysm and the venous thrombosis events were respectively 99.13% (95% CI 86.21-100) and 86.48 % (95% CI 71.81-97.15).
CONCLUSION: Our systematic review and meta-analysis support the use of infliximab in patients with severe and/or refractory vascular Behçet's disease, particularly in cases involving pulmonary artery aneurysms.
METHODS: We searched PubMed, Scopus, Web of Science, and Cochrane Library databases for eligible studies. Meta-analysis of proportions was performed. Heterogeneity was assessed with Cochrane's Q test and I2 statistics. Random effects models were used for all statistical analyses which were conducted on R software (version 4.4.2), PROSPERO registry number CRD42025640970.
RESULTS: Of the 2127 results initially identified, 11 studies with a total of 284 patients were included in the final analysis. Infliximab induced complete vascular response in 78.17% of patients (95% CI 63.11-90.61). The remission rates in the subgroups of patients with pulmonary artery aneurysm and the venous thrombosis events were respectively 99.13% (95% CI 86.21-100) and 86.48 % (95% CI 71.81-97.15).
CONCLUSION: Our systematic review and meta-analysis support the use of infliximab in patients with severe and/or refractory vascular Behçet's disease, particularly in cases involving pulmonary artery aneurysms.